Compugen Ltd. (NASDAQ:CGEN) was the recipient of unusually large options trading on Wednesday. Investors purchased 3,352 call options on the stock. This represents an increase of 922% compared to the average volume of 328 call options.
A number of hedge funds have recently made changes to their positions in CGEN. Matrix Asset Advisors Inc. NY boosted its stake in Compugen by 1.4% in the first quarter. Matrix Asset Advisors Inc. NY now owns 107,000 shares of the biotechnology company’s stock worth $919,000 after purchasing an additional 1,500 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Compugen by 10.0% during the second quarter. Van ECK Associates Corp now owns 23,952 shares of the biotechnology company’s stock worth $198,000 after buying an additional 2,174 shares during the period. Artisan Partners Limited Partnership boosted its position in Compugen by 0.3% during the second quarter. Artisan Partners Limited Partnership now owns 758,145 shares of the biotechnology company’s stock valued at $6,277,000 after purchasing an additional 2,361 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Compugen by 13.1% in the second quarter. Virtus ETF Advisers LLC now owns 26,285 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 3,049 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Compugen by 29.9% in the second quarter. ProShare Advisors LLC now owns 15,035 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 3,459 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ CGEN opened at $6.53 on Thursday. Compugen has a one year low of $5.76 and a one year high of $18.75. The firm has a market capitalization of $446.78 million, a PE ratio of -15.55 and a beta of 2.32. The business has a 50-day moving average price of $6.44 and a two-hundred day moving average price of $7.36.
Separately, Zacks Investment Research cut Compugen from a “buy” rating to a “hold” rating in a research note on Monday, October 4th.
Compugen Company Profile
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Featured Story: What is a Candlestick Chart?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.